trial
as of 2026-07-01Long-term Study of Cariprazine in Patients With Schizophrenia
NCTId NCT01104792
at a glance
Phase 3 · Completed
Enrollment 752 (actual)
Sponsored by Forest Laboratories
Primary completion 2013-01-31
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
752 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2010-05-31
Primary completion
2013-01-31
Eligibility
ALL · 18 Years · 60 Years
Interventions & indications
Indications
Sponsors
Forest LaboratoriesLead Sponsor
Gedeon Richter Ltd.Collaborator
Investigators
1
Raffaele Migliore, MAStudy Director
Sites
86 total
Little Rock, United StatesLittle Rock, United StatesLittle Rock, United StatesSpringdale, United StatesCarson, United StatesCerritos, United StatesCosta Mesa, United StatesCosta Mesa, United StatesGarden Grove, United StatesGarden Grove, United StatesLong Beach, United StatesOceanside, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
752
Phase
PHASE3
Primary Completion Date
2013-01-31
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
company
collaborator
company
indication
investigator
person